Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 4/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.40 |
| ▸ | PIK3C3 | Q8NEB9 | 3/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.36 |
| ▸ | CHEK1 | O14757 | 3/20 | 0.35 |
| ▸ | TTBK1 | Q5TCY1 | 1/20 | 0.35 |
| ▸ | TNIK | Q9UKE5 | 1/20 | 0.35 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.34 |
| ▸ | CLK2 | P49760 | 2/20 | 0.34 |
| ▸ | CDK5 | Q00535 | 2/20 | 0.34 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.34 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.34 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.34 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29705375 | 1.00 | FGFR1 (0.40) | FGFR1FGFR2FGFR3PIK3C3BRAF | |
| SCHEMBL12344590 | 0.74 | PIK3C3 (0.37) | FGFR1PIK3C3BRAFCHEK1AKT1 | |
| SCHEMBL29705478 | 0.73 | MAPT (0.50) | FGFR1PIK3C3BRAFCHEK1AKT1 | |
| SCHEMBL11982852 | 0.73 | PIK3C3 (0.36) | FGFR1PIK3C3BRAFCHEK1AKT1 | |
| SCHEMBL15243458 | 0.73 | NOS1 (0.50) | FGFR1PIK3C3BRAFCHEK1AKT1 | |
| SCHEMBL10329 | 0.73 | DYRK1A (0.50) | FGFR1PIK3C3CHEK1MAP4K4CLK2 | |
| SCHEMBL3429629 | 0.73 | PIK3C3 (0.36) | FGFR1PIK3C3BRAFCHEK1AKT1 | |
| SCHEMBL1496196 | 0.73 | MAPT (0.50) | FGFR1PIK3C3BRAFCHEK1AKT1 | |
| SCHEMBL27077213 | 0.73 | PIK3C3 (0.36) | FGFR1PIK3C3BRAFCHEK1AKT1 | |
| SCHEMBL2619214 | 0.73 | CCR1 (0.46) | PIK3C3CHEK1AKT1PIK3CAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | ONCODESIGN PRECISION MEDICINE (FR) | 2026-02-10 | — | — | US | disclosed |
| EP-4146658-B1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PREC MEDICINE OPM (FR) | 2025-10-29 | — | — | EP | disclosed |
| WO-2025076632-A1 | COMPOUNDS AND USES THEREOF | FIBROCOR THERAPEUTICS INC. (CA) | 2025-04-17 | — | — | WO | disclosed |
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PRECISION MEDICINE (FR) | 2023-11-09 | — | — | US | disclosed |
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | ONCODESIGN PRECISION MEDICINE (FR) | 2023-11-09 | — | — | US | disclosed |
| CN-115996932-A | New macrocyclic LRRK2 kinase inhibitors | 法国施维雅药厂 | 2023-04-21 | — | — | CN | disclosed |
| EP-4146658-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | Les Laboratoires Servier (FR) | 2023-03-15 | — | — | EP | disclosed |
| US-20220306640-A1 | HYDANTOIN DERIVATIVE | ONO PHARMACEUTICAL CO., LTD. (JP) | 2022-09-29 | — | — | US | disclosed |
| WO-2021224320-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2021-11-11 | — | — | WO | disclosed |
| WO-2021224320-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | LES LABORATOIRES SERVIER (FR) | 2021-11-11 | — | — | WO | disclosed |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | CS PHARMATECH LIMITED (KY) | 2020-04-30 | — | — | US | disclosed |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | CS PHARMATECH LIMITED (KY) | 2019-10-08 | — | — | US | disclosed |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | HIGH GREAT INVESTMENT LIMITED (HK) | 2019-01-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12545689-B2 | Macrocyclic LRRK2 kinase inhibitors | LRRK2, SNCA, ROS1 | FGFR1 959/4885FGFR2 1434/4885FGFR3 663/4885 |
| US-10435388-B2 | Selective inhibitors of clinically important mutants of the EGFR tyrosine kinase | EGFR, ERBB3, ERBB2 | FGFR1 31/4885FGFR2 28/4885FGFR3 15/4885 |
| US-20200131176-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | FGFR1 26/4885FGFR2 22/4885FGFR3 12/4885 |
| US-20190023689-A1 | SELECTIVE INHIBITORS OF CLINICALLY IMPORTANT MUTANTS OF THE EGFR TYROSINE KINASE | EGFR, ERBB3, ERBB2 | FGFR1 31/4885FGFR2 28/4885FGFR3 15/4885 |
| US-20220306640-A1 | HYDANTOIN DERIVATIVE | DDR1, DDR2, DDRGK1 | FGFR1 225/4885FGFR2 817/4885FGFR3 612/4885 |
| US-20230357269-A1 | NEW MACROCYCLIC LRRK2 KINASE INHIBITORS | LRRK2, RIN1, GRK3 | FGFR1 902/4885FGFR2 1579/4885FGFR3 1173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.